Sarepta Elevidys EU Rejection - Search News

News

Sarepta Shares Fall

InvestorsHub on MSN · 4d

Sarepta shares drop after EU regulators reject Elevidys gene therapy

Shares of Sarepta Therapeutics Inc. (NASDAQ:SRPT) plunged 13% on Friday after a major regulatory blow in Europe. The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion on Elevidys,

Bloomberg on MSN · 4d

Sarepta Shares Fall After EU Regulator Rejects Gene Therapy

Sarepta Therapeutics Inc. shares plunged after European regulators rejected its gene therapy Elevidys, intensifying scrutiny on the drugmaker after it was pressured to halt shipments of its treatment in the US.

The Business Journals · 18h

Sarepta's FDA woes raise questions for future of gene therapy treatments

Despite all the buzz around Sarepta and concerns about Elevidys, industry watchers aren’t convinced this current controversy is a nail in the coffin for gene therapy.

Investing.com South Africa4d

Sarepta stock falls after Elevidys fails to get backing by EU regulators

The European Medicines Agency’s drug advisory committee (CHMP) rejected Elevidys for children aged 3 to 7 years who are able ...

Sarepta Fallout Continues With EU’s Negative Opinion of Elevidys in Ambulatory Patients

The European Union’s health regulatory agency did not endorse approving Elevidys for ambulatory patients with Duchenne ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results